证券代码:300142 证券简称:沃森生物 | --- | --- | --- | |----------------------|----------------------------------------------------|----------| | | | 2023-012 | | | √ 特定对象调研 | | | 投资者关系活动类别 | □ 媒体采访 □ □ 新闻发布会 □ □ 现场参观 | | | | □ 其他( ) | | | | 广发基金 薛继锐 | | | 参与单位名称及 | 富达基金 翟端亭 | | | 人员姓名 | 银华基金 | | | | 国海富兰克林基金 | | | 时间 | 2023 年 9 月 4 | | | 地点 | 电话会议 | | | 上市公司接待人员姓名 | 董事会秘书 刘宇然投资者关系经理 投资者关系助理专员 | | | | 2023 年 9 月 4 | | 与公司进行了沟通交流,本次沟通交流涉及的主要内容如下: 1、今年上半年公司 13 价肺炎结合疫苗海外业务有取得新突破吗? 2023 年上半年,公司获得了 13 价肺炎结合疫苗孟加拉国注册证和 泰国注册证,其 ...

云南沃森生物技术股份有限公司 2023 年半年度报告全文 云南沃森生物技术股份有限公司 WALVAX 沃森生物 2023 年半年度报告 2023-083 2023 年 8 月 1 云南沃森生物技术股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李云春、主管会计工作负责人周华及会计机构负责人（会计 主管人员）吴昌雄声明：保证本半年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公 司对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分，详细披露了公司经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 WALVAX沃森生 ...

证券代码：300142 证券简称：沃森生物 云南沃森生物技术股份有限公司投资者关系活动记录表 编号：2023-010 | --- | --- | |------------------------|--------------------| | | 分析师会议 | | 投资者关系活动类别 | 业绩说明会路演活动 | | | | | | | | 参与单位名称及人员姓名 | | | | | | 时间 | | | 地点 | | | 上市公司接待人员姓名 | 周兵 | 调研人员就公司相关情况与公司进行了沟通交流，本次沟通交流 涉及的主要内容如下： 1、公司上半年经营情况如何？预计半年度和全年的业绩是怎样 的？ 目前公司正在进行 2023 年半年度财务核算工作，上半年的数据正 在核算中，具体请以后续定期报告披露为准。公司一季度实现营业总收 投资者关系活动 主要内容介绍 入 8.33 亿元，同比增长 27.04%，实现归属于上市公司股东的净利润 1.72 亿元，同比增长 345.34%，主要的增长动力来源于 13 价肺炎结合疫苗、 23 价肺炎多糖疫苗销售收入增加及新增双价 HPV 疫苗销售收入。从 产品生产上看，公司各 ...

证券代码：300142 证券简称：沃森生物 云南沃森生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |------------------------|------------------------------------------|---------------------|----------| | | | | 2023-009 | | | √ 特定对象调研 | 分析师会议 | | | 投资者关系活动类别 | □ 媒体采访 □ □ 新闻发布会 □□ 现场参观 | 业绩说明会 路演活动 | | | | □ 其他（ ） | | | | 参与单位名称及人员姓名 | 益民基金 高喜阳太平洋证券 谭紫媚东海证券 | | | | 时间 | 2023 年 5 月 18 日、 | | | | 地点 | 昆明 | | | | 上市公司接待人 | 董事会秘书 刘宇然 | | | | 员姓名 | 投资者关系经理 | | | | | 2023 年 5 月 18 | | | 了沟通交流，本次沟通交流涉及的主要内容如下： 1、HPV 疫苗市场情况如何？公司双价 HPV 疫苗的销售情况 ...

云南沃森生物技术股份有限公司 2023 年第一季度报告 证券代码：300142 证券简称：沃森生物 公告编号：2023-041 云南沃森生物技术股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证 季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|--------------------------| | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | 营业收 ...

Financial Performance - The total revenue for 2022 was 1.5 billion CNY, representing a year-on-year increase of 15%[3]. - The company achieved a net profit of 300 million CNY in 2022, up 20% compared to the previous year[3]. - The company's operating revenue for 2022 was ¥5,086,445,195.10, representing a 46.89% increase compared to ¥3,462,831,094.14 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥728,652,009.34, a 70.35% increase from ¥427,747,681.59 in 2021[12]. - The net profit after deducting non-recurring gains and losses was ¥859,124,544.51, up 45.33% from ¥591,146,772.49 in 2021[12]. - The basic earnings per share for 2022 was ¥0.4546, a 66.70% increase from ¥0.2727 in 2021[12]. - The cash flow from operating activities for 2022 was ¥1,201,491,008.09, a 70.36% increase from ¥705,276,750.42 in 2021[12]. - The company reported a quarterly revenue of ¥1,692,153,912.48 in Q2 2022, which was the highest among the four quarters[14]. - The company reported a total revenue of ¥1.86 billion from its subsidiary Guangzhou Watson, with a net profit of approximately ¥62.64 million[94]. - The company reported a total shareholding of 63,005,970 shares at the end of the reporting period, with a net decrease of 10,608,625 shares due to various transactions[115]. Market Expansion and Product Development - User data indicated a 25% increase in vaccine sales volume, with a total of 10 million doses sold in 2022[3]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[3]. - New product development includes a novel mRNA vaccine, expected to enter clinical trials in Q3 2023[3]. - Future guidance estimates a revenue growth of 20% for 2023, driven by new product launches and market expansion[3]. - The company is actively pursuing internationalization and import substitution strategies to enhance its market presence[31]. - The company aims to accelerate the development of new vaccines, including mRNA vaccines for COVID-19 variants and a nine-valent HPV vaccine, to meet market demand[98]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[126]. - The company is committed to a comprehensive internationalization strategy, aiming to complete WHO pre-certification for key products and expand into international markets[98]. Research and Development - The company is exploring strategic acquisitions to enhance its R&D capabilities, with a budget of 500 million CNY allocated for this purpose[3]. - The company’s R&D efforts include multiple vaccines in various clinical stages, including the nine-valent HPV vaccine and the new mRNA vaccines for COVID-19[36]. - The company has a stable R&D team with over 210 employees holding doctoral or master's degrees, enhancing its innovation capabilities[46]. - The company is committed to building a smart factory through digital integration of production quality management and cold chain logistics monitoring[39]. - The company has established a modern vaccine production base in Yuxi, Yunnan, capable of large-scale production of multiple vaccine varieties, adhering to WHO PQ pre-certification standards[46]. - The company is actively involved in the research and development of new products, particularly in the vaccine sector[120]. Financial Management and Investments - The company has received government subsidies amounting to ¥111,110,270.61 in 2022, which was an increase compared to ¥71,773,119.15 in 2021[18]. - The company has made significant equity investments, including ¥100 million in Shanghai Zerun Biotechnology Co., holding a 56.61% stake, and ¥50 million in Guangzhou Watson Health Technology Co., acquiring a 100% stake[75]. - The total investment amount for the reporting period was ¥660 million, a decrease of 60.23% compared to ¥1.66 billion in the same period last year[74]. - The company has a long-term commitment to avoid related transactions with Watson Bio after the completion of the asset restructuring[192]. - The company has a commitment to ensure that any future stock incentive plans are linked to the execution of its compensation measures[193]. Corporate Governance and Compliance - The company has established a comprehensive quality management system to ensure the delivery of qualified, safe, and effective drugs to end users, adhering to various regulations such as the Drug Administration Law and Vaccine Management Law[101]. - The company has implemented strict anti-fraud, anti-money laundering, and anti-bribery management systems to mitigate compliance risks[169]. - The company has established a risk management department in its subsidiary to identify, prevent, and control risks in the production and quality management processes, implementing risk-based management throughout the production process[102]. - The company has maintained a stable governance structure, ensuring that shareholders, especially minority shareholders, can exercise their rights effectively[104]. - The company has a dispersed shareholding structure, with no single shareholder able to control the board or the company[109]. Environmental Responsibility - The company has implemented a series of environmental protection projects, including the mRNA COVID-19 vaccine industrialization project, which received approval in August 2021 and passed environmental acceptance in November 2022[177]. - The company has established pollution control facilities, including one wastewater treatment facility and two air pollution control facilities, all of which are operating normally[179]. - The company is committed to maintaining compliance with environmental regulations and enhancing corporate governance to protect shareholder interests, particularly for minority shareholders[175]. - The company has received multiple environmental impact assessment approvals for various projects, ensuring compliance with local environmental regulations[177]. - The company aims to create a production system with minimal environmental impact, promoting green and low-carbon development[185]. Shareholder Relations and Communication - The company emphasizes the importance of maintaining investor relations and has adhered to its investor relations management system throughout the reporting period[106]. - The company conducted a performance online briefing on April 6, 2022, to enhance investor understanding of its development strategy and operational management[106]. - The company maintains regular communication with investors through various channels, ensuring timely responses to inquiries[108]. - The company has established designated media for information disclosure, ensuring equal access to information for all shareholders[108]. - The company held its 2021 Annual General Meeting on April 12, 2022, with an investor participation rate of 18.67%[111]. Employee Management and Development - The total number of employees at the end of the reporting period was 2,249, with 1,602 in production roles[141]. - The company has implemented a new performance management system in 2022 to enhance the connection between organizational and individual performance results[143]. - The company has established a talent management project, establishing 6 talent standard models to optimize its talent management system[145]. - The company has expanded its training programs to include a wider range of participants, enhancing understanding of compliance and operational standards among subsidiary staff[175]. - The company has implemented employee stock ownership and stock option incentive plans to enhance talent retention and organizational cohesion[143].